> 本文内容由[载脂蛋白A1](https://zh.wikipedia.org/wiki/载脂蛋白A1)转换而来。


**載脂蛋白A1**（，簡稱**ApoA1**）為附著於[高密度脂蛋白](../Page/高密度脂蛋白.md "wikilink")（HDL）及[乳靡小球上的](https://zh.wikipedia.org/wiki/乳靡小球 "wikilink")[載脂蛋白](https://zh.wikipedia.org/wiki/載脂蛋白 "wikilink")，基因編碼為「*APOA1*」\[1\]\[2\]。載脂蛋白A1可以活化（Lecithin Cholesterol Acyltransferase，LCAT）；當[高密度脂蛋白](../Page/高密度脂蛋白.md "wikilink")運送[組織中多餘的](https://zh.wikipedia.org/wiki/组织_\(生物学\) "wikilink")[膽固醇](../Page/膽固醇.md "wikilink")回到[肝臟](../Page/肝臟.md "wikilink")[細胞中時](https://zh.wikipedia.org/wiki/細胞 "wikilink")，載脂蛋白A1同時也可作為高密度脂蛋白的[配體](../Page/配體.md "wikilink")，在中扮演重要角色。研究指出，*APOA1*的mRNA是由反義RNA轉譯出的內源性蛋白質所調控\[3\]。

## 結構

APOA1基因位於第11對染色體上（11q23-q24），該基因包含4個外顯子\[4\]。载脂蛋白A1的質量為45.4 kDa ，含有 396 個胺基酸；質譜分析可觀察到蛋白質由21個胜肽片段組成\[5\]\[6\]。

## 功能

載脂蛋白A1（ApoA1）為構成血漿中[高密度脂蛋白](../Page/高密度脂蛋白.md "wikilink")（HDL）蛋白質部分的主要成分。小腸腸道細胞所分泌的[乳糜微粒中雖然也含有載脂蛋白A](https://zh.wikipedia.org/wiki/乳糜微粒 "wikilink")1，但在血流中很快就會被轉為HDL\[7\]。ApoA1可促進將周邊組織脂質及[膽固醇](../Page/膽固醇.md "wikilink")回收至[肝臟](../Page/肝臟.md "wikilink")，並藉由膽管分泌至小腸。另外該蛋白也是（LCAT）的輔因子，製造了血漿中大多數的。ApoA1同時也是[前列环素](../Page/前列环素.md "wikilink")（PGI2）的穩定因子，因此也具有抗凝血的作用\[8\]。如果編碼該蛋白的基因有缺陷，會導致個體體內缺乏HDL，導致包含在內的症狀，以及非神經性全身[類澱粉變性](../Page/淀粉样变.md "wikilink")\[9\]。

由於ApoA1在體內脂質代謝的角色相當重要，因此常被視為預測個體冠心病風險的生物標記。有研究發現「apoB-100/apoA1」的比值預測[心肌梗塞的效果比任何其他脂質標記更有效果](https://zh.wikipedia.org/wiki/心肌梗塞 "wikilink")\[10\]。ApoA1可利用[ELISA或](../Page/酶联免疫吸附试验.md "wikilink")檢驗。

## 臨床意義

### Activity associated with high HDL-C and protection from heart disease

As a major component of the [high-density lipoprotein](../Page/高密度脂蛋白.md "wikilink") complex (**protective "fat removal" particles**), apo A1 helps to clear fats, including [cholesterol](../Page/膽固醇.md "wikilink"), from white blood cells within artery walls, making the WBCs less likely to become fat overloaded, transform into foam cells, die and contribute to progressive . Five of nine men found to carry a mutation (E164X) who were at least 35 years of age had developed premature [coronary artery disease](../Page/冠狀動脈疾病.md "wikilink").\[11\]One of four mutants of apo A1 is present in roughly 0.3% of the Japanese population, but is found in 6% of those with low HDL cholesterol levels.

**** is a naturally occurring mutant of apo A1, found in a few families in [Limone sul Garda](https://zh.wikipedia.org/wiki/利莫内苏尔加尔达 "wikilink"), Italy, and, by genetic + church record family tree detective work, traced to a single individual in the 14th century. Described in 1980, it was the first known molecular abnormality of [apolipoproteins](../Page/载脂蛋白.md "wikilink").\[12\]Paradoxically, carriers of this mutation have very low HDL-C (HDL-Cholesterol) levels, but no increase in the risk of heart disease, often living to age 100 or older. This unusual observation was what lead Italian investigators to track down what was going on and lead to the discovery of apo A1 Milano (the city, Milano, \~160 km away, in which the researcher's lab was located). Biochemically, apo A1 contains an extra [cysteine](../Page/半胱氨酸.md "wikilink") bridge, causing it to exist as a [homodimer](../Page/蛋白二聚体.md "wikilink") or as a [heterodimer](../Page/蛋白二聚体.md "wikilink") with apo A-II. However, the enhanced cardioprotective activity of this mutant (which likely depends on fat & cholesterol efflux) cannot easily be replicated by other cysteine mutants.\[13\]

Recombinant apo A1 Milano dimers formulated into liposomes can reduce s in animal models by up to 30%.\[14\]Apo A1 Milano has also been shown in small clinical trials to have a statistically significant effect in reducing (reversing) plaque build-up on arterial walls.\[15\]\[16\]

In human trials the reversal of plaque build-up was measured over the course of five weeks.\[17\]\[18\]

### Novel Haplotypes within apolipoprotein AI-CIII-AIV gene cluster

Lately, two novel susceptibility haplotypes i.e. P2-S2-X1 and P1-S2-X1 have been discovered in ApoAI-CIII-AIV gene cluster on chromosome 11q23, which confer approximately threefold higher risk of coronary heart disease in normal\[19\]as well as in the patients having non-insulin diabetes mellitus.\[20\]

### Role in other diseases

A G/A [polymorphism](../Page/多态性_\(生物学\).md "wikilink") in the [promoter](../Page/啟動子.md "wikilink") of the apo A1 gene has been associated with the age at which patients presented with [Alzheimer disease](https://zh.wikipedia.org/wiki/阿兹海默病 "wikilink").\[21\]Protection from Alzheimer's disease by apo A1 may rely on a synergistic interaction with .\[22\] [Amyloid](../Page/類澱粉蛋白.md "wikilink") deposited in the knee following surgery consists largely of apo A1 secreted from [chondrocytes](../Page/软骨细胞.md "wikilink") ([cartilage](../Page/软骨.md "wikilink") cells).\[23\]A wide variety of [amyloidosis](../Page/淀粉样变.md "wikilink") symptoms are associated with rare Apo A1 mutants.

Apo A-I binds to [lipopolysaccharide](../Page/脂多糖.md "wikilink") or [endotoxin](../Page/脂多糖.md "wikilink"), and has a major role in the anti-endotoxin function of HDL.\[24\]

In one study, a decrease in apo A1 levels was detected in [schizophrenia](../Page/精神分裂症.md "wikilink") patients' [CSF](../Page/腦脊液.md "wikilink"), brain and peripheral tissues. \[25\]

### Epistatic impact of apo A1

Apolipoprotein A1 and APOE interact epistatically to modulate triglyceride levels in coronary heart disease patients. Individually, neither apo A1 nor apo E was found to be associated with triglyceride (TG) levels, but pairwise epistasis (additive x additive model) explored their significant synergistic contributions with raised TG levels (P\<0.01). \[26\]

### Factors affecting apo A1 activity

Apo A1 production is decreased by [calcitriol](../Page/骨化三醇.md "wikilink"), and increased by a drug that antagonizes it.\[27\]

Exercise or [statin](../Page/羟甲基戊二酸单酰辅酶A还原酶抑制剂.md "wikilink") treatment may cause an increase in HDL-C levels by inducing apo A1 production, but this depends on the G/A promoter polymorphism.\[28\]

## 交互作用

載脂蛋白A1可與下列蛋白產生[交互作用](../Page/蛋白質交互作用.md "wikilink")：

  - \[29\]

  - \[30\]and

  - \[31\]

### Potential binding partners

Apolipoprotein A1 binding precursor, a relative of APOA-1 abbreviated , has a predicted biochemical interaction with . The relationship between these two proteins is substantiated by [cooccurance across genomes](https://zh.wikipedia.org/wiki/cooccurance_across_genomes "wikilink") and [coexpression](https://zh.wikipedia.org/wiki/coexpression "wikilink").\[32\]The ortholog of CARKD in *E. coli* contains a domain not present in any eukaryotic ortholog. This domain has a high sequence identity to APOA1BP. CARKD is a protein of unknown function, and the biochemical basis for this interaction is unknown.

### 交互作用途徑

## 參見

  - [载脂蛋白B](https://zh.wikipedia.org/wiki/载脂蛋白B "wikilink")

  - [心血管疾病](../Page/心血管疾病.md "wikilink")

  -
## 參考文獻

## 外部連結

  -
  - [Applied Research on Apolipoprotein-A1](https://www.mabtech.com/knowledge-center/applied-research/apolipoproteins)

[Category:载脂蛋白](https://zh.wikipedia.org/wiki/Category:载脂蛋白 "wikilink")

1.
2.
3.
4.
5.  \]
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.